|
US4082845A
(en)
|
1977-04-25 |
1978-04-04 |
Merck & Co., Inc. |
3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
|
|
JPS5665863U
(https=)
|
1979-10-25 |
1981-06-02 |
|
|
|
JPS5665863A
(en)
|
1979-10-31 |
1981-06-03 |
Tokyo Organ Chem Ind Ltd |
Novel aniline derivative, its preparation and pesticide containing the same
|
|
JPS625888Y2
(https=)
|
1980-08-14 |
1987-02-10 |
|
|
|
JPS5738777A
(en)
|
1980-08-19 |
1982-03-03 |
Sogo Yatsukou Kk |
2-sufanilamidopyrathyn derivative
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5643755A
(en)
|
1994-10-07 |
1997-07-01 |
Regeneron Pharmaceuticals Inc. |
Nucleic acid encoding tie-2 ligand
|
|
US5879672A
(en)
|
1994-10-07 |
1999-03-09 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligand 1
|
|
DE69534180T2
(de)
|
1994-09-22 |
2006-03-02 |
Licentia Ltd. |
Promotor der tie rezeptor protein kinase
|
|
WO1998004689A1
(en)
|
1995-07-31 |
1998-02-05 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
ZA971896B
(en)
|
1996-03-26 |
1998-09-07 |
Du Pont Merck Pharma |
Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
|
|
KR100567649B1
(ko)
|
1996-09-25 |
2006-04-05 |
아스트라제네카 유케이 리미티드 |
혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
|
|
US6030831A
(en)
|
1997-09-19 |
2000-02-29 |
Genetech, Inc. |
Tie ligand homologues
|
|
NZ503432A
(en)
|
1997-09-26 |
2002-11-26 |
Zentaris Gmbh |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
|
AU776788C
(en)
|
1998-12-16 |
2005-10-27 |
Warner-Lambert Company |
Treatment of arthritis with MEK inhibitors
|
|
JP2002534380A
(ja)
|
1999-01-07 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
Ｍｅｋ阻害剤による喘息の治療
|
|
AU3475900A
(en)
|
1999-01-29 |
2000-08-18 |
University Of Akron, The |
Polyimides used as microelectronic coatings
|
|
JP2003504400A
(ja)
|
1999-07-16 |
2003-02-04 |
ワーナー−ランバート・カンパニー |
Ｍｅｋ阻害剤を用いた慢性痛の治療方法
|
|
GB2356398A
(en)
|
1999-11-18 |
2001-05-23 |
Lilly Dev Ct S A |
Preparation of arylsulfamides
|
|
WO2001046196A1
(en)
|
1999-12-21 |
2001-06-28 |
Sugen, Inc. |
4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
|
|
US6492529B1
(en)
|
2000-01-18 |
2002-12-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Bis pyrazole-1H-pyrazole intermediates and their synthesis
|
|
AU2002232439A1
(en)
|
2000-11-29 |
2002-06-11 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
KR20020096367A
(ko)
|
2001-06-19 |
2002-12-31 |
주식회사 티지 바이오텍 |
관절염 예방 또는 치료제 및 그것의 스크리닝 방법
|
|
JP2004536845A
(ja)
*
|
2001-07-11 |
2004-12-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介疾患の治療方法
|
|
NZ532780A
(en)
|
2001-12-21 |
2006-10-27 |
Wellcome Trust |
Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
TW200406374A
(en)
*
|
2002-05-29 |
2004-05-01 |
Novartis Ag |
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
|
|
US20060128783A1
(en)
|
2002-08-09 |
2006-06-15 |
Dinsmore Christopher J |
Tyrosine kinase inhibitors
|
|
US20060141472A1
(en)
|
2003-03-20 |
2006-06-29 |
Miikka Vikkula |
Medical use of ras antagonists for the treatment of capillary malformation
|
|
AU2004246800B2
(en)
|
2003-06-13 |
2008-12-04 |
Novartis Ag |
2-aminopyrimidine derivatives as Raf kinase inhibitors
|
|
WO2005080377A1
(ja)
|
2004-02-20 |
2005-09-01 |
Kirin Beer Kabushiki Kaisha |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
|
TW200616974A
(en)
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
|
BRPI0514691A
(pt)
|
2004-08-31 |
2008-06-17 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
|
|
WO2006040568A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Quinoxalines as b raf inhibitors
|
|
GB0423554D0
(en)
*
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
WO2006071940A2
(en)
|
2004-12-23 |
2006-07-06 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
|
EP1960394A2
(en)
|
2005-11-15 |
2008-08-27 |
Bayer HealthCare AG |
Pyrazolyl urea derivatives useful in the treatment of cancer
|
|
JP2009518298A
(ja)
*
|
2005-12-01 |
2009-05-07 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌治療に有用な尿素化合物
|
|
CN101365682A
(zh)
|
2005-12-08 |
2009-02-11 |
千禧药品公司 |
具有激酶抑制活性的双环化合物
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
AU2007245495A1
(en)
|
2006-04-26 |
2007-11-08 |
Astex Therapeutics Limited |
Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
EP1992628A1
(en)
|
2007-05-18 |
2008-11-19 |
Glaxo Group Limited |
Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
|
|
WO2008044688A1
(en)
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
US7790756B2
(en)
*
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
|
WO2009007934A2
(en)
|
2007-07-10 |
2009-01-15 |
Neurim Pharmaceuticals (1991) Ltd. |
Cd44 splice variants in neurodegenerative diseases
|
|
AU2008337286B2
(en)
*
|
2007-12-19 |
2014-08-07 |
Cancer Research Technology Limited |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
GB0807609D0
(en)
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
MY159230A
(en)
|
2008-10-02 |
2016-12-30 |
Respivert Ltd |
P38 map kinase inhibitors
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
JP5670912B2
(ja)
|
2008-12-11 |
2015-02-18 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
IN2012DN01403A
(https=)
|
2009-08-24 |
2015-06-05 |
Genentech Inc |
|
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
|
NZ601085A
(en)
*
|
2010-02-01 |
2015-04-24 |
Cancer Rec Tech Ltd |
1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
|
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
|
EP2556068B1
(en)
|
2010-04-08 |
2019-01-23 |
Respivert Limited |
P38 map kinase inhibitors
|
|
WO2011124923A2
(en)
|
2010-04-08 |
2011-10-13 |
Respivert Limited |
Novel compounds
|
|
GB201010196D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Methods
|
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
|
GB201010193D0
(en)
|
2010-06-17 |
2010-07-21 |
Respivert Ltd |
Medicinal use
|
|
WO2012008564A1
(ja)
|
2010-07-16 |
2012-01-19 |
協和発酵キリン株式会社 |
含窒素芳香族複素環誘導体
|
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
|
EP2701694A4
(en)
|
2011-04-28 |
2014-10-08 |
Univ Duke |
METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
EA025266B1
(ru)
|
2011-06-23 |
2016-12-30 |
Ваймет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
|
JP2014528928A
(ja)
|
2011-09-01 |
2014-10-30 |
ノバルティス アーゲー |
ヌーナン症候群の治療のための有機化合物の使用
|
|
CN103917536B
(zh)
|
2011-10-03 |
2016-07-06 |
瑞斯比维特有限公司 |
1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂
|
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
US20150225373A1
(en)
|
2012-08-29 |
2015-08-13 |
Respivert Limited |
Kinase inhibitors
|
|
EP2890701B1
(en)
|
2012-08-29 |
2017-03-29 |
Respivert Limited |
Kinase inhibitors
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
US20150210722A1
(en)
|
2012-08-29 |
2015-07-30 |
Respivert Limited |
Kinase inhibitors
|
|
WO2014076484A1
(en)
|
2012-11-16 |
2014-05-22 |
Respivert Limited |
Kinase inhibitors
|
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
|
JO3279B1
(ar)
|
2013-03-15 |
2018-09-16 |
Respivert Ltd |
مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
|
|
US9771353B2
(en)
|
2013-04-02 |
2017-09-26 |
Topivert Pharma Limited |
Kinase inhibitors based upon N-alkyl pyrazoles
|
|
KR102283876B1
(ko)
|
2013-04-02 |
2021-07-29 |
옥슬러 액퀴지션즈 리미티드 |
키나제 저해제로서 유용한 우레아 유도체
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
EP3083604A1
(en)
|
2013-12-20 |
2016-10-26 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
|
ES2677595T3
(es)
|
2014-02-14 |
2018-08-03 |
Respivert Limited |
Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
|
|
EP3201189A1
(en)
|
2014-10-01 |
2017-08-09 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|